A phase I/II trial of AB928 in combination with AB122 in cancer patients.

Trial Profile

A phase I/II trial of AB928 in combination with AB122 in cancer patients.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs AB-122 (Primary) ; AB-928 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 20 Nov 2017 New trial record
    • 13 Nov 2017 According to an Arcus Biosciences media release, the company is planning to initiate this trial during the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top